A Phase 3, Randomized, Double-Blind Study of Pembrolizumab plus Ipilimumab vs Pembrolizumab plus Placebo in Previously Untreated, Stage IV, Metastatic Non-small Cell Lung Cancer Subjects Whose Tumors are PD-L1 Positive (TPS ? 50%) (KEYNOTE-598)
Supported projects > Other Supported Projects · 2018
Authors: Tuncay GÖKSEL
2018-2021, Other Supported Projects, R & D Project, Continues